AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer

Autores
Priolo, C.; Pyne, S.; Rose, J.; Regan, E.R.; Zadra, G.; Photopoulos, C.; Cacciatore, S.; Schultz, D.; Scaglia, Natalia; McDunn, J.; De Marzo, A.M.; Loda, M.
Año de publicación
2014
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic response to different oncogenic drivers or a particular oncogenic event results in its own metabolic reprogramming. Akt and Myc are arguably the most prevalent driving oncogenes in prostate cancer. Mass spectrometry-based metabolite profiling was performed on immortalized human prostate epithelial cells transformed by AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a prostate-specific promoter, and human prostate specimens characterized for the expression and activation of these oncoproteins. Integrative analysis of these metabolomic datasets revealed that AKT1 activation was associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated with dysregulated lipid metabolism. Selected metabolites that differentially accumulated in the MYC-high versus AKT1-high tumors, or in normal versus tumor prostate tissue by untargeted metabolomics, were validated using absolute quantitation assays. Importantly, the AKT1/MYC status was independent of Gleason grade and pathologic staging. Our fi ndings show how prostate tumors undergo a metabolic reprogramming that refl ects their molecular phenotypes, with implications for the development of metabolic diagnostics and targeted therapeutics.
Instituto de Investigaciones Bioquímicas de La Plata
Facultad de Ciencias Médicas
Materia
Ciencias Médicas
Cáncer
Espectrometría de Masas
AKT1
MYC
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/85055

id SEDICI_f0576fb6e672f462f98c0f904efda327
oai_identifier_str oai:sedici.unlp.edu.ar:10915/85055
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancerPriolo, C.Pyne, S.Rose, J.Regan, E.R.Zadra, G.Photopoulos, C.Cacciatore, S.Schultz, D.Scaglia, NataliaMcDunn, J.De Marzo, A.M.Loda, M.Ciencias MédicasCáncerEspectrometría de MasasAKT1MYCCancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic response to different oncogenic drivers or a particular oncogenic event results in its own metabolic reprogramming. Akt and Myc are arguably the most prevalent driving oncogenes in prostate cancer. Mass spectrometry-based metabolite profiling was performed on immortalized human prostate epithelial cells transformed by AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a prostate-specific promoter, and human prostate specimens characterized for the expression and activation of these oncoproteins. Integrative analysis of these metabolomic datasets revealed that AKT1 activation was associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated with dysregulated lipid metabolism. Selected metabolites that differentially accumulated in the MYC-high versus AKT1-high tumors, or in normal versus tumor prostate tissue by untargeted metabolomics, were validated using absolute quantitation assays. Importantly, the AKT1/MYC status was independent of Gleason grade and pathologic staging. Our fi ndings show how prostate tumors undergo a metabolic reprogramming that refl ects their molecular phenotypes, with implications for the development of metabolic diagnostics and targeted therapeutics.Instituto de Investigaciones Bioquímicas de La PlataFacultad de Ciencias Médicas2014-10-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdf7198-7204http://sedici.unlp.edu.ar/handle/10915/85055enginfo:eu-repo/semantics/altIdentifier/issn/0008-5472info:eu-repo/semantics/altIdentifier/doi/10.1158/0008-5472.can-14-1490info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-03T10:48:37Zoai:sedici.unlp.edu.ar:10915/85055Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-03 10:48:37.371SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
title AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
spellingShingle AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
Priolo, C.
Ciencias Médicas
Cáncer
Espectrometría de Masas
AKT1
MYC
title_short AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
title_full AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
title_fullStr AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
title_full_unstemmed AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
title_sort AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer
dc.creator.none.fl_str_mv Priolo, C.
Pyne, S.
Rose, J.
Regan, E.R.
Zadra, G.
Photopoulos, C.
Cacciatore, S.
Schultz, D.
Scaglia, Natalia
McDunn, J.
De Marzo, A.M.
Loda, M.
author Priolo, C.
author_facet Priolo, C.
Pyne, S.
Rose, J.
Regan, E.R.
Zadra, G.
Photopoulos, C.
Cacciatore, S.
Schultz, D.
Scaglia, Natalia
McDunn, J.
De Marzo, A.M.
Loda, M.
author_role author
author2 Pyne, S.
Rose, J.
Regan, E.R.
Zadra, G.
Photopoulos, C.
Cacciatore, S.
Schultz, D.
Scaglia, Natalia
McDunn, J.
De Marzo, A.M.
Loda, M.
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Ciencias Médicas
Cáncer
Espectrometría de Masas
AKT1
MYC
topic Ciencias Médicas
Cáncer
Espectrometría de Masas
AKT1
MYC
dc.description.none.fl_txt_mv Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic response to different oncogenic drivers or a particular oncogenic event results in its own metabolic reprogramming. Akt and Myc are arguably the most prevalent driving oncogenes in prostate cancer. Mass spectrometry-based metabolite profiling was performed on immortalized human prostate epithelial cells transformed by AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a prostate-specific promoter, and human prostate specimens characterized for the expression and activation of these oncoproteins. Integrative analysis of these metabolomic datasets revealed that AKT1 activation was associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated with dysregulated lipid metabolism. Selected metabolites that differentially accumulated in the MYC-high versus AKT1-high tumors, or in normal versus tumor prostate tissue by untargeted metabolomics, were validated using absolute quantitation assays. Importantly, the AKT1/MYC status was independent of Gleason grade and pathologic staging. Our fi ndings show how prostate tumors undergo a metabolic reprogramming that refl ects their molecular phenotypes, with implications for the development of metabolic diagnostics and targeted therapeutics.
Instituto de Investigaciones Bioquímicas de La Plata
Facultad de Ciencias Médicas
description Cancer cells may overcome growth factor dependence by deregulating oncogenic and/or tumor-suppressor pathways that affect their metabolism, or by activating metabolic pathways de novo with targeted mutations in critical metabolic enzymes. It is unknown whether human prostate tumors develop a similar metabolic response to different oncogenic drivers or a particular oncogenic event results in its own metabolic reprogramming. Akt and Myc are arguably the most prevalent driving oncogenes in prostate cancer. Mass spectrometry-based metabolite profiling was performed on immortalized human prostate epithelial cells transformed by AKT1 or MYC, transgenic mice driven by the same oncogenes under the control of a prostate-specific promoter, and human prostate specimens characterized for the expression and activation of these oncoproteins. Integrative analysis of these metabolomic datasets revealed that AKT1 activation was associated with accumulation of aerobic glycolysis metabolites, whereas MYC overexpression was associated with dysregulated lipid metabolism. Selected metabolites that differentially accumulated in the MYC-high versus AKT1-high tumors, or in normal versus tumor prostate tissue by untargeted metabolomics, were validated using absolute quantitation assays. Importantly, the AKT1/MYC status was independent of Gleason grade and pathologic staging. Our fi ndings show how prostate tumors undergo a metabolic reprogramming that refl ects their molecular phenotypes, with implications for the development of metabolic diagnostics and targeted therapeutics.
publishDate 2014
dc.date.none.fl_str_mv 2014-10-16
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/85055
url http://sedici.unlp.edu.ar/handle/10915/85055
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/0008-5472
info:eu-repo/semantics/altIdentifier/doi/10.1158/0008-5472.can-14-1490
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.format.none.fl_str_mv application/pdf
7198-7204
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1842260362114629632
score 13.13397